All In Biotech

Drug Trial Radar · NCT00006206

COMBINE (Acamprosate/Naltrexone)

COMBINE: Effect of Combined Pharmacotherapies and Behavioral Interventions

Last checked: Nov 19, 2026Latest source record: May 3, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,375 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,375

Actual

Start

Aug 1997

Primary completion

Not stated

Study completion May 2006

Sponsor

Lead sponsor
University of North Carolina, Chapel HillAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute on Alcohol Abuse and Alcoholism (NIAAA); Lipha Pharmaceuticals
First posted
Sep 12, 2000

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Combine is a multicenter, randomized clinical trial that will evaluate combinations of three interventions for treating alcohol dependence. The goal is to determine whether improvement in treatment outcomes can be achieved by various combinations of drug and behavioral interventions. Two of the interventions will consist of pharmacological treatment with naltrexone (Revia) or acamprosate (Campral). The third intervention is a multicomponent behavioral therapy including such components as motivational enhancement therapy, cognitive behavioral therapy, and referral to self-help groups, including AA. All three interventions will include a component supporting compliance to medications and reduction in drinking.

Conditions

  • Alcoholism

Interventions

  • naltrexone (Revia)Drug

  • acamprosate (Campral)Drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent days abstinent
  2. Time to relapse to heavy drinking

Locations

12 sites in 1 country. Site status is shown where the registry gives one.

  • Substance Abuse Treatment Unit, Yale University

    New Haven, Connecticut

  • University of Miami School of Medicine

    Miami, Florida

  • Harvard University/McLean Hospital

    Belmont, Massachusetts

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Boston University School of Medicine

    Boston, Massachusetts

  • Center on Alcoholism, Substance Abuse and Addiction, University of New Mexico

    Albuquerque, New Mexico

  • Treatment and Research Center, University of Pennsylvania

    Philadelphia, Pennsylvania

  • Roger Williams Medical Center , Brown University

    Providence, Rhode Island

  • Center for Alcohol Programs, Medical University of South Carolina

    Charleston, South Carolina

  • Southwest Texas Addiction Research and Technology Center, University of Texas Health Science Center

    San Antonio, Texas

  • Addictions Treatment Center, University of Washington

    Seattle, Washington

  • University of Wisconsin-Milwaukee

    Milwaukee, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.